Considering that elevation Lp‐PLA2 contributes about 2‐fold risk for strokes or coronary artery disease, testing for Lp‐PLA2 might be a supplementary evaluation tool to classical cardiovascular risk assessment. This evidence concerns the gene PLA2G7 and coronary artery disorder.